These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 32232111)
21. The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes. Johansen NJ; Knop FK Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):311-317. PubMed ID: 36639124 [TBL] [Abstract][Full Text] [Related]
22. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Saiz LC; Gorricho J; Garjón J; Celaya MC; Muruzábal L; Malón MDM; Montoya R; López A Cochrane Database Syst Rev; 2017 Oct; 10(10):CD010315. PubMed ID: 29020435 [TBL] [Abstract][Full Text] [Related]
24. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
25. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Saiz LC; Gorricho J; Garjón J; Celaya MC; Erviti J; Leache L Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010315. PubMed ID: 30027631 [TBL] [Abstract][Full Text] [Related]
26. Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation. Cheng HS; Njock MS; Khyzha N; Dang LT; Fish JE Front Genet; 2014; 5():422. PubMed ID: 25540650 [TBL] [Abstract][Full Text] [Related]
27. Krüppel-Like Factors in Vascular Inflammation: Mechanistic Insights and Therapeutic Potential. Sweet DR; Fan L; Hsieh PN; Jain MK Front Cardiovasc Med; 2018; 5():6. PubMed ID: 29459900 [TBL] [Abstract][Full Text] [Related]
28. Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander? Muhammad K; Ayoub MA; Iratni R Curr Pharm Des; 2021; 27(18):2141-2150. PubMed ID: 33461451 [TBL] [Abstract][Full Text] [Related]
29. The brain-gut axis, inflammatory bowel disease and bioelectronic medicine. Eberhardson M; Levine YA; Tarnawski L; Olofsson PS Int Immunol; 2021 Jun; 33(6):349-356. PubMed ID: 33912906 [TBL] [Abstract][Full Text] [Related]
31. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]